FDA draft drug-delivery device guidance
Published November 4, 2026 · Coverage October 25–31, 2026, Pacific · Lower priority
FDA announced revised draft guidance on drug-delivery performance information for certain devices and device constituent parts of combination products. The notice describes recommendations for development and regulatory submissions; the draft is not a universal healthcare-facility mandate or a binding final guidance.
Suggested owner and action: Device and combination-product development teams can assess whether the draft recommendations affect their own development or regulatory submissions; healthcare facilities should not treat the draft as a universal mandate.
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →